Ciphergen notified of Nasdaq non-compliance

Ciphergen Biosystems (Fremont, California) reported that it has received notification that it has failed to comply with Nasdaq National Market requirements for continuing listing because the market value of its listed securities has fallen below $50 million for 10 consecutive business days the Company has been provided until June 23 to regain compliance.

Ciphergen Biosystems is focused on translating protein biomarkers and panels of biomarkers into protein molecular diagnostic tests that improve patient care and on providing R&D services through its Biomarker Discovery Center laboratories. The company manufactures a family of ProteinChip Systems and services for clinical, research and process proteomics applications.